BMI

Smart Weight, Body Composition, and BMI Scales Market size is set to grow by USD 108.54 million from 2024-2028, Rising health consciousness among people boost the market, Technavio

Retrieved on: 
Friday, June 14, 2024

The inclusion of these features is expected to boost the global demand for smart weight, body composition, and BMI scales during the forecast period.

Key Points: 
  • The inclusion of these features is expected to boost the global demand for smart weight, body composition, and BMI scales during the forecast period.
  • The Smart Weight, Body Composition, and BMI Scales market is witnessing significant growth due to increasing health consciousness among consumers.
  • Bodyweight is just one aspect of health, and body composition analysis provides a more comprehensive understanding of overall health.
  • Lastly, consumer education and awareness about the importance of body composition analysis and the benefits of using smart scales is essential to drive market growth.

Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024

Retrieved on: 
Monday, June 3, 2024

These results were among six Rhythm presentations at the Endocrine Society Annual Meeting & Expo (ENDO 2024) being held June 1-4 in Boston.

Key Points: 
  • These results were among six Rhythm presentations at the Endocrine Society Annual Meeting & Expo (ENDO 2024) being held June 1-4 in Boston.
  • After one year of treatment with setmelanotide, improvements of at least one obesity class were observed across all cohorts (HO: 92%; POMC deficiency: 89%; LEPR deficiency: 36%; BBS: 42%).
  • Treatment was well-tolerated and stable weight and food intake reductions and improved insulin sensitivity were observed after three weeks.
  • Dr. Roth presented the design of Rhythm’s first-in-human Phase 1 trial of once-weekly RM-718 in individuals with obesity or patients with HO.

Glyscend Doses First Patient in a Phase 2 Obesity Trial of GLY-200, a First-in-Class Oral Polymeric Drug Candidate for the Treatment of Metabolic Disease

Retrieved on: 
Monday, June 3, 2024

Glyscend Therapeutics , a clinical-stage biopharmaceutical company advancing first-in-class oral polymeric drugs for the treatment of metabolic disease, today announced the initiation of a Phase 2 clinical trial of its lead candidate, GLY-200, as a novel oral treatment for obesity.

Key Points: 
  • Glyscend Therapeutics , a clinical-stage biopharmaceutical company advancing first-in-class oral polymeric drugs for the treatment of metabolic disease, today announced the initiation of a Phase 2 clinical trial of its lead candidate, GLY-200, as a novel oral treatment for obesity.
  • This ongoing Phase 2 trial is designed to evaluate the efficacy, safety, and tolerability of GLY-200 in a non-diabetic obese population.
  • Obesity and type 2 diabetes affect hundreds of millions of people who need well-tolerated and effective ways to manage their disease.
  • Enrollment is underway at five sites across the US, and Glyscend anticipates results from the Phase 2 trial in the first quarter of 2025.

31% of Australians are obese – is Ozempic a healthy solution? A GP considers Johann Hari’s inside take on a ‘mass experiment’

Retrieved on: 
Monday, June 3, 2024

Obesity levels for adults have hit 26% in Britain and 42.5% in the United States, journalist Johann Hari writes in his new book, Magic Pill.

Key Points: 
  • Obesity levels for adults have hit 26% in Britain and 42.5% in the United States, journalist Johann Hari writes in his new book, Magic Pill.
  • Worried about his health, he says, he accessed Ozempic though a doctor, “after some brief questions and some cursory measuring”.
  • Review: Magic Pill: The Extraordinary Benefits and Disturbing Risks of the New Weight-Loss Drugs – Johann Hari (Bloomsbury)

‘As a GP … this is even better’

  • In my opinion, as a GP and a reader, this is even better.
  • “This is a mass experiment, carried out on millions of people, and I am one of the guinea pigs,” he writes.
  • However, he knows from lived experience and observations gathered through his journalism that the science of obesity is only part of the picture.

‘He does not hold back’

  • In particularly, some of us in healthcare, who have developed whiplash from watching weight-loss drugs and diets come and go, will have a great deal of scepticism.
  • He does not hold back as he names, considers, explores and then reconsiders the use of this medication in his own life.
  • I believe the references to scientific studies, as well as his own personal thoughts, hold up to scrutiny.

Addressing stigma head-on

  • He argues that the obesity-promoting environment we are experiencing is something we created over the past 50 or so years – and therefore something we can reverse.
  • Currently, unhealthy food is cheap, easy to come by and heavily promoted (even to children).
  • I appreciated the way Hari addressed the stigma of obesity head-on.
  • Any weight loss that does not involve some kind of suffering (extreme calorie restriction, exercise) is often seen as “cheating”.

What does Ozempic do to us?

  • Scientist Daniel Drucker was trying to find out if the molecule GLP-1 (a small part of glucagon, which our guts produce) had any function by itself.
  • When he mixed GLP-1 with insulin synthesising cells, he was excited to see those cells were stimulated to produce insulin.
  • For a several decades, scientists worked hard to bring GLP-1 from a petri dish to become a safe and usable medication in humans.

Food and pleasure

  • Even more compelling reading to me, however, was the drug’s impact on the relationship between food and pleasure.
  • As a GP, I’ve been trained to see a loss of pleasure in food as potentially pathological, signalling an underlying problem.
  • Enjoyment of food is a fundamental human experience that has kept humans alive.
  • Why is giving up the pleasure we get from eating seen as a reasonable exchange for losing weight?

What do we really want?

  • Incredibly, much of what the Japanese have done to achieve this has been within two generations.
  • They have prioritised healthy food being both obtainable and understood, by everyone: from children to the elderly.
  • They eat slowly, mixing flavours and textures, and are careful to balance each meal nutritionally as well as aesthetically.
  • In Hari’s opinion, most governments (Japan excepted) hesitate to regulate these kinds of food in ways that will improve health.
  • The implicit ensuing question is: what am I/what are we going to do about it?

Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy

Retrieved on: 
Thursday, May 23, 2024

SAN DIEGO, May 23, 2024 (GLOBE NEWSWIRE) -- A number of accomplished medical and scientific experts presented critical new research on sleep conditions and their effect on cardiovascular health at the American Thoracic Society International Conference. The ResMed-supported research provided new insights into the effectiveness of PAP therapy in treating sleep-disordered breathing and its associated clinical benefits. The studies were among 26 supported by ResMed (NYSE: RMD, ASX: RMD) in collaboration with leading scientists including Michael Arzt, MD, Universitätsklinikum Regensburg, Germany; Jean-Louis Pépin, MD, Grenoble Alpes University, France; Atul Malhotra, MD, University of California, San Diego; and Holger Woehrle, Ulm Lung Centre, Germany.

Key Points: 
  • The ResMed-supported research provided new insights into the effectiveness of PAP therapy in treating sleep-disordered breathing and its associated clinical benefits.
  • Several studies demonstrated findings showing continued effectiveness of PAP therapies for patients with sleep disorder conditions like obstructive sleep apnea.
  • This finding demonstrates a correlation between the use of PAP therapy and a reduction in use of healthcare resources.
  • Two studies evaluated the effects of Adaptive Servo-Ventilation (ASV) therapy in two populations, patients with TE-CSA and patients on long-term opioid therapy.

Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024

Retrieved on: 
Wednesday, May 22, 2024

REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that data from the randomized withdrawal period of Study C602 of DCCR (diazoxide choline) extended-release tablets in Prader-Willi Syndrome (PWS) will be featured in an oral presentation at the Annual Meeting of the Endocrine Society (ENDO 2024), being held June 1-4, 2024 in Boston, Massachusetts.

Key Points: 
  • REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that data from the randomized withdrawal period of Study C602 of DCCR (diazoxide choline) extended-release tablets in Prader-Willi Syndrome (PWS) will be featured in an oral presentation at the Annual Meeting of the Endocrine Society (ENDO 2024), being held June 1-4, 2024 in Boston, Massachusetts.
  • Details of the presentation are as follows:
    Withdrawal of DCCR (Diazoxide Choline) Extended-Release Tablets Worsens Hyperphagia and Increases Weight and BMI in a 16-week Double-blind, Placebo-controlled, Randomized Withdrawal Period in Patients with Prader Willi Syndrome

Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome

Retrieved on: 
Wednesday, May 22, 2024

People living with BBS may experience insatiable hunger, also known as hyperphagia, and severe obesity beginning early in life.

Key Points: 
  • People living with BBS may experience insatiable hunger, also known as hyperphagia, and severe obesity beginning early in life.
  • “Hyperphagia – the feeling of extreme hunger that stays with patients all the time – leads to early-onset, life-long, severe obesity that affects many aspects of daily living.
  • Until now there have been no licensed treatments for obesity and hyperphagia caused by BBS.”
    The final NICE recommendation is aligned to the European Marketing Authorization (EMA) and U.K.
  • Rhythm is moving ahead with submission to the Scottish Medicines Consortium with a decision expected in 2025.

At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Demonstrates Superiority in Phase i Clinical Trial in Overweight and Obese People With Type 2 Diabetes

Retrieved on: 
Monday, May 20, 2024

With no concentrated (>200 U/mL), rapid acting insulins on the market, AT278 has potential to be the first, and only, insulin available to the growing number of patients with high daily insulin requirements.

Key Points: 
  • With no concentrated (>200 U/mL), rapid acting insulins on the market, AT278 has potential to be the first, and only, insulin available to the growing number of patients with high daily insulin requirements.
  • They further add to the positive results from our previous clinical study in Type 1 diabetic patients, where superiority was also demonstrated.
  • AT278 has the potential to be the only highly concentrated, ultra-rapid acting insulin to enable the next generation of miniaturised, longer wear insulin pumps.
  • Pharmacokinetics and Pharmacodynamics of a Novel U500 Insulin Aspart Formulation: A Randomized, Double-Blind, Crossover Study in People With Type 1 Diabetes Care 2023;46(4):757–764: https://doi.org/10.2337/dc22-1054

Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity

Retrieved on: 
Wednesday, May 22, 2024

This data will be presented by Mo Qatanani, Ph.D., Chief Scientific Officer, at Scholar Rock’s Investor Event, which begins today at 8:30 a.m.

Key Points: 
  • This data will be presented by Mo Qatanani, Ph.D., Chief Scientific Officer, at Scholar Rock’s Investor Event, which begins today at 8:30 a.m.
  • Primary data from EMBRAZE are expected in mid-2025 and will inform Scholar Rock’s development of SRK-439 towards an anticipated IND filing in 2025.
  • The presentation from Scholar Rock’s Investor Day will be available in the Investors and Media section of Scholar Rock’s website.
  • Live webcast of the event may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com .

Study in the Journal of the American Heart Association Links Hello Heart Usage to Significant Reductions in Blood Pressure, Cholesterol, and Weight

Retrieved on: 
Monday, May 20, 2024

A new peer-reviewed study in the Journal of the American Heart Association found that Hello Heart ’s digital heart health program was associated with reductions in blood pressure (BP), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and weight.

Key Points: 
  • A new peer-reviewed study in the Journal of the American Heart Association found that Hello Heart ’s digital heart health program was associated with reductions in blood pressure (BP), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and weight.
  • The study is the largest and most robust of its kind to date, examining 102,475 Hello Heart users with high BP (hypertension) between January 2018 and December 2022.
  • Users were equipped with Hello Heart’s connected heart health monitor and mobile app with digital coaching.
  • The Hello Heart monitor and app recorded BP, heart rate, and the appearance of irregular heartbeat.